Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.52 |
| ▸ | CA1 | P00915 | 17/20 | 0.52 |
| ▸ | CA12 | O43570 | 16/20 | 0.52 |
| ▸ | CA9 | Q16790 | 16/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7059253 | 0.85 | PKM (0.39) | CA2CA1CA12CA9PKM | |
| SCHEMBL2087081 | 0.78 | PKM (0.40) | PKM | |
| SCHEMBL13742979 | 0.75 | CA2 (0.55) | CA2CA1CA12CA9CHEK1 | |
| SCHEMBL23254983 | 0.74 | APP (0.57) | CA2CA1CA12CA9CA4 | |
| SCHEMBL18118201 | 0.74 | CA1 (0.56) | CA2CA1CA12CA9CA4 | |
| SCHEMBL13743183 | 0.74 | CA2 (0.56) | CA2CA1CA12CA9CA4 | |
| SCHEMBL17785542 | 0.73 | CA2 (0.64) | CA2CA1CA12CA9CA4 | |
| SCHEMBL2880094 | 0.73 | HTT (0.39) | PKM | |
| SCHEMBL4802533 | 0.72 | CA2 (0.53) | CA2CA1CA12CA9CA4 | |
| SCHEMBL5635594 | 0.71 | CA2 (0.59) | CA2CA1CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163778-B2 | Pyridines as FBPase inhibitors for treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| CN-102026978-A | Pyridine compounds | HOFFMANN LA ROCHE | 2011-04-20 | — | — | CN | disclosed |
| EP-2227452-A2 | PYRIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009068468-A2 | PYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143439-A1 | NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143439-A1 | NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES | FBP1, PDXK, G6PC1 | CA2 1000/4885CA1 2939/4885CA12 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.